Trial Information
Inclusion Criteria:
- histologically confirmed metastatic colorectal cancer patients Having initiated
treatment with bevacizumab
Exclusion Criteria:
- non-metastatic colorectal cancer patients not recieved bevacizumab
Type of Study:
Observational [Patient Registry]
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Objective response rate
Outcome Description:
To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice
Outcome Time Frame:
6 weeks
Safety Issue:
No
Principal Investigator
Lin Shen, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Beijing Cancer Hopital
Authority:
China: Food and Drug Administration
Study ID:
CGOG2001
NCT ID:
NCT01860144
Start Date:
June 2012
Completion Date:
December 2013
Related Keywords:
- Metastatic Colorectal Cancer
- bevacizumab
- overall survival
- adverse events
- tumor resection rate
- Colorectal Neoplasms